Leading Tech & Life Sciences Law Firm joins WoHX

Leading Tech & Life Sciences Law Firm joins WoHX
By: Women's HealthX Editorial

Boston, MA -- October 12: Women's HealthX is pleased to welcome Orrick as a sponsor for this year's event in Boston.

As the women's health sector experiences rapid growth, life sciences and digital health companies face an increasingly complex web of regulatory hurdles, data privacy concerns, clinical trial design challenges, and fundraising headwinds.; Orrick is tackling this challenge by providing world-class legal and strategic guidance for high-growth tech and life sciences companies.

From navigating FDA regulatory pathways to structuring the legal frameworks for decentralized clinical trials, Orrick helps healthcare innovators scale safely and efficiently.

By helping companies break down accessibility barriers in clinical research, Orrick provides biopharma sponsors with the robust legal and compliance foundation required to accelerate trial timelines and bring targeted therapies to market faster.

"The firm's expertise perfectly complements the Evidence, Data & Innovation track at Women's HealthX. Throughout the event, life sciences leaders will discuss how capturing representative biological data and navigating regulatory frameworks is key to overcoming commercial bottlenecks and ensuring new therapeutics actually reach the women who need them."

To move beyond the limitations of traditional trial designs, biopharma needs strategic legal partners who understand the intersection of healthcare, compliance, and technology. Orrick is providing the infrastructure to make that a reality.

We are delighted to welcome Orrick to the Women's HealthX community and look forward to showcasing their work this December.

Women’s HealthX 2026 | From Rhetoric to Results

Encore Boston Harbor | December 3-4 2026

Bypass abstract market rhetoric to evaluate real-world health economics, regulatory compliance mandates, and care delivery systems. Join the region's foremost health plan medical directors, hospital COOs, biopharma innovators, and enterprise benefits buyers anchoring our 2026 tracks.